The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | BrECADD versus BEACOPP in advanced HL: a German Hodgkin Study Group investigation
Jakub Svoboda, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, discusses a German study comparing the BrECADD regimen (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone) to BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) for advanced Hodgkin lymphoma (HL). The study found BrECADD to have encouraging efficacy, and Dr Svoboda is excited to see how this regimen will integrate into the US treatment landscape. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role: Adaptive Biotechnologies; AstraZeneca; Atara Biotherapeutics; BMS; Crispr therapeutics; Pharmacyclics; Seagen. Research Funding: Adaptive Biotechnologies (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Kite, a Gilead company (Inst); Merck (Inst); Pharmacyclics (Inst); Seagen (Inst); TG Therapeutics (Inst).
